Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network
- PMID: 19142989
- PMCID: PMC2928479
- DOI: 10.1002/hep.22724
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network
Abstract
Adult nonalcoholic fatty liver disease (NAFLD) is characterized by absent or mild portal chronic inflammation (CI); in children, portal CI may be predominant. This study correlated clinical features with portal CI. Centrally-graded biopsies and temporally-related clinical parameters from 728 adults and 205 children. From the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) were evaluated. Mild, more than mild and no portal CI were found in 60%, 23% and 16% of adult biopsies and 76%, 14% and 10% of pediatric biopsies. Autoantibodies, and elevated alanine aminotransferase were not associated with portal CI. Clinical features associated with "more than mild" in adults were older age (P < 0.0001), female gender (P = 0.001), higher body mass index (P < 0.0001), elevated insulin levels (P = 0.001), higher homeostasis model assessment of insulin resistance score (HOMA-IR) (P < 0.0001), and medications used for NAFLD (P = 0.0004), diabetes (P < 0.0001), and hypertension (P < 0.0001). "More than mild" in the pediatric biopsies correlated with younger age (P = 0.01), but not with body mass index, insulin or HOMA-IR. In both groups, lobular and portal inflammation scores had no association, but there was an association with definite steatohepatitis (P < 0.0001). Features associated in the adult biopsies with "more than mild" were steatosis amount (P = 0.01) and location (P < 0.0001), ballooning (P < 0.0001), and advanced fibrosis (P < 0.0001). In the pediatric biopsies, "more than mild" was associated with steatosis location (P = 0.0008) and fibrosis score (P < 0.0001), specifically, the portal/periportal fibrosis or greater fibrosis) (P < 0.01).
Conclusion: Increased portal CI is associated with many clinical and pathologic features of progressive NAFLD in both adults and children, but not with ALT, autoantibodies, or lobular inflammation. More than mild portal CI in liver biopsies of untreated NAFLD may be considered a marker of advanced disease.
Comment in
-
Portal inflammation as index of steatohepatitis in children with nonalcoholic fatty liver disease.Hepatology. 2009 Aug;50(2):659. doi: 10.1002/hep.23114. Hepatology. 2009. PMID: 19637193 No abstract available.
References
-
- Zatloukal K, Denk H, Stumptner C, et al. From Mallory to Mallory-Denk inclusion bodies: what, how and why? Experimental Cell Research. 2007;313:2033–49. - PubMed
-
- Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641–9. - PubMed
-
- Nobili V, Marcellini M, Devito R, et al. NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44:458–65. - PubMed
-
- Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Seminars in Diagnostic Pathology. 2005;22:330–8. - PubMed
-
- Brunt EM, Ramrakhiani S, Cordes BG, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol. 2003;16:49–56. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01DK061713/DK/NIDDK NIH HHS/United States
- U01 DK061732/DK/NIDDK NIH HHS/United States
- U01DK061731/DK/NIDDK NIH HHS/United States
- U01DK061737/DK/NIDDK NIH HHS/United States
- U01 DK061731/DK/NIDDK NIH HHS/United States
- U01 DK061718/DK/NIDDK NIH HHS/United States
- U01DK061718/DK/NIDDK NIH HHS/United States
- U01DK061728/DK/NIDDK NIH HHS/United States
- U01 DK061730/DK/NIDDK NIH HHS/United States
- U01 DK061728/DK/NIDDK NIH HHS/United States
- M01 RR000065/RR/NCRR NIH HHS/United States
- U01 DK061738/DK/NIDDK NIH HHS/United States
- U01 DK061734/DK/NIDDK NIH HHS/United States
- U01DK061738/DK/NIDDK NIH HHS/United States
- U01 DK061737/DK/NIDDK NIH HHS/United States
- U01 DK061713/DK/NIDDK NIH HHS/United States
- UL1 RR024989/RR/NCRR NIH HHS/United States
- M01 RR000188/RR/NCRR NIH HHS/United States
- P30 DK056341/DK/NIDDK NIH HHS/United States
- U01DK061732/DK/NIDDK NIH HHS/United States
- M01 RR000750/RR/NCRR NIH HHS/United States
- M01 RR000827/RR/NCRR NIH HHS/United States
- U01DK061734/DK/NIDDK NIH HHS/United States
- U01DK061730/DK/NIDDK NIH HHS/United States
- M01 RR020359/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous